



Illinois Prescription Monitoring Program

August 2026 Update



Subscribe to @ILPMP on YouTube

UPDATES

New Illinois Law Expands Prescription History Checking Requirements Prior To Prescribing



Please Note: An incorrect effective date was included in the previously published article below. We apologize for any confusion this may have caused. The article has been corrected and is being republished with the accurate effective date of January 1, 2027.

Illinois [Public Act 104-0512](#), effective **January 1, 2027**, expands the ILPMP prescription checking requirements. Each prescriber or prescriber's designee shall document an attempt to access and review the patient's ILPMP profile prior to prescribing any C-II opioid, C-IV benzodiazepine, and an initial C-II stimulant prescription. This expanded checking requirement

reflects ILPMP's continued commitment to supporting safe prescribing practices, improving patient safety, and advancing public health initiatives across Illinois.



Upcoming ILPMP Advisory Committee Meeting Scheduled for September 22, 2026

The ILPMP Advisory Committee will meet on September 22, 2026, from 12:00 to 1:30 CST. The meeting will bring together committee members, stakeholders, and partners to review program updates.

Agenda highlights:

- ILPMP Opioid Treatment Program data update
- Introduction of new members
- Department of Justice grant award
- ILPMP Legislative & Rule update
- ILPMP Pharmacy Compliance update

The full agenda and meeting link for Webex can be found at [ILPMP Advisory Committee](#) the week of September 14th.



ILPMP Staff Attend Illinois Pharmacist Association Annual Conference

Megan Conant and Jackie DeNardo, IL PMPnow Coordinators, represented ILPMP at the Illinois Pharmacist Association (IPhA) annual conference on August 29, 2026, in East Peoria, Illinois. This conference gives ILPMP the opportunity to connect with pharmacists and pharmacy technicians across Illinois, share program updates and resources, and better understand the needs of pharmacy professionals.



International Overdose Awareness Day To Be Held on August 31, 2026

#END OVERDOSE

The ILPMP proudly observes International Overdose Awareness Day on August 31st, which is a global event aimed at increasing awareness of overdose prevention strategies and destigmatizing substance use so that all Illinoisans are provided with compassionate care. Visit overdoseday.com to find an event near you.

PENINGTON
INSTITUTE



International Overdose
Awareness Day

EDUCATIONAL RESOURCES

Continuing Education Modules Now Available For Pharmacists: Supporting Improved Care for Patients with Opioid Use Disorder and Opioid Overdose

Two new continuing education modules have been developed in partnership with Southern Illinois University Edwardsville. These modules have been released to enhance clinical decision making when managing patients with opioid use disorder (OUD) and caring for patients following an opioid overdose. These



no-cost modules are designed to support healthcare professionals with practical, evidence-based strategies that can be applied directly in clinical settings.

Module 13: Buprenorphine Initiation Dosing Methods for Opioid Use Disorder (OUD)

Module 13 provides an in-depth overview of current buprenorphine initiation methods, including traditional induction, micro-dosing, and high-dose initiation strategies. Learners will gain insight into selecting appropriate dosing approaches based on patient needs, reducing barriers to treatment initiation, and improving treatment retention for individuals with OUD.

Module 14: Clinical Management of Patients After Opioid Overdose

Module 14 focuses on best practices for post-overdose care, emphasizing the critical window of opportunity to engage patients in treatment. The module covers acute clinical management, risk assessment, harm-reduction strategies, linkage to OUD treatment, and approaches to support ongoing recovery. It also highlights the role of compassionate, patient-centered care following overdose events.

Illinois Pharmacists Association (IPhA) offers these modules free of charge and is accredited by the Accreditation Council for Pharmacy Education. Click [HERE](#) to register.



SAMHSA ADVISORY
Substance Abuse and Mental Health
Services Administration

JUNE 2026

EXPANDING ACCESS TO MEDICATIONS FOR OPIOID USE DISORDER: THE ROLE OF PHARMACISTS AND THE SETTINGS IN WHICH THEY WORK

According to the 2024 National Survey on Drug Use and Health, about 8 million people ages 12 and older reported experiencing symptoms of opioid use disorder (OUD) in the past year.¹ Over 80,000 opioid-involved overdose deaths occurred in the 12 months ending April 2025, based on provisional data. Many of these deaths were likely associated with high-potency synthetic opioids, such as fentanyl, nitazenes, and medetomidine, all of which are increasingly present in the drug supply.²⁻⁴ Xalazine, a nonopioid sedative approved only for voluntary use, is also proliferating in the drug supply and is associated with more than 10 percent of overdose deaths, often in combination with opioids.⁵

Buprenorphine, methadone, and naltrexone are effective, evidence-based medications for opioid use disorder (MOUD) that support long-term recovery and are approved by the Food and Drug Administration (FDA) for the treatment of OUD.⁶ MOUD are evidence-based treatments that can substantially reduce cravings and symptoms related to OUD, reduce OUD-related stress and death, and support long-term recovery.⁷ Despite the effectiveness of MOUD, significantly fewer people receive these lifesaving medications than could benefit from them.⁸


Many factors influence this unmet need, including prescribing hesitancy and stigma related to MOUD and people with OUD. Other barriers to accessing treatment include a lack of available providers, transportation, and otherwise financial constraints, and living in a rural or remote area.⁹⁻¹¹ Expanding access to MOUD in pharmacies and strengthening the role of pharmacists in supporting the delivery of these treatments have been noted in the field as potential approaches for increasing use of MOUD among people with OUD.¹²

This Advisory provides pharmacists, substance use disorder (SUD) treatment providers, and public health and public policy professionals with information about how pharmacists and the settings in which they work can help support expanding access to MOUD. Specifically, the Advisory describes opportunities for pharmacists to integrate MOUD treatment into their practices, highlights how some states permit pharmacists to prescribe specific types of MOUD, discusses what pharmacy leaders and managers can do to support access to MOUD, describes the points of service where integration of MOUD treatment services can occur, and addresses maintaining and expanding the ordering of MOUD. Importantly, pharmacists' roles are presented within the context of collaborative practice and team-based care, complementing the work of prescribers, mental health professionals, and other providers. Finally, the Advisory suggests ways to address barriers to providing OUD treatment services in pharmacies.

Advisory: Expanding Access to Medications for Opioid Use Disorder: The Role of Pharmacists and the Settings in Which They Work

Released June 2026

[Click to Read Full SAMHSA Advisory](#)



Click [HERE](#) to register for Personalized Medicine in Pain / Substance Use Disorder (SUD)

VIRTUAL ASK THE EXPERT SERIES

PERSONALIZED MEDICINE IN PAIN / SUD
SEPTEMBER 17, 2026 12:00PM CST

PRESENTED BY:
JAKE NICHOLS, PHARM D, MBA
CHIEF MEDICAL OFFICER
IGNITE BIOMEDICAL

SPONSORED BY
ILPMP
Illinois Prescription Monitoring Program

MODERATED BY:
CHRIS HERNDON, PHARM D
PROFESSOR, SIUE

NOTE THIS SESSION IS NOT APPROVED FOR CONTINUING EDUCATION

[REGISTER](#)

<https://tinyurl.com/tbdecprjk>

The Safe Opioid Prescribing Series

Target Audience: Prescribers and Pharmacists

Cost: **FREE**

Register for (10) 30-minute online modules collectively fulfilling 5 hours CME credit.

[Register For CME Modules](#)

Navigating Pain Management, Safe Opioid Prescribing, Opioid Use Disorder

Target Audience: Pharmacists

Cost: **FREE**

Register for (10) 30-minute online modules collectively fulfilling 5 hours CE credit.

[Register for CE Modules](#)

Data Quality in Prescription Monitoring Programs

Target Audience: Pharmacists, Pharmacy Technicians, Dispensing Practitioners, and any other Data Submitters

Cost: **FREE**

Free ACPE accredited educational opportunity providing 1 hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with NASCSA and 12 prescription monitoring program (PMP) administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity. **If you received credit for this CE prior to 10/20/25, this CE opportunity is available to you again to participate in and receive credit.**

<https://ce.talemhealth.com/a/LPMBSE>

[Register For CE](#)

ILPMP.ORG & Illinois PMPnow [Monthly Data Totals](#)

ILPMP.org & IL PMPnow Totals

July 2026



					
585	99,425	75,413	249,015	1,919	12,437,473
NEW USERS IN JULY	TOTAL USERS	TOTAL ILPMP PRESCRIBER USERS	TOTAL ILPMP WEBSITE REQUESTS	TOTAL IL PMPNOW CONNECTIONS	TOTAL IL PMPNOW REQUESTS

CONTACT US

✉ **DHS.DBHR.PharmacyCompliance@illinois.gov**
✉ **DHS.DBHR.PMPnow@illinois.gov**
✉ **DHS.PMP@illinois.gov**
🌐 **ILPMP.ORG**



The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data for Schedule II–V controlled substances, except for testosterone. In addition, the ILPMP requires the reporting of select drugs of interest and provides access to other relevant health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.

Illinois Prescription Monitoring Program | 401 North 4th Street | Springfield, IL 62702 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email & social marketing for free!